At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.
Close
WGS GeneDx Holdings
Post-Mkt 08-05 16:14:23 EDT
69.91
-0.99
-1.40%
盘后69.89
-0.02-0.03%
16:13 EDT
High72.44Low68.12Vol866.98K
Open69.77D1 Closing70.90Amplitude6.09%
Mkt Cap2.07BTradable Cap1.33BTotal Shares29.68M
T/O60.95MT/O Rate4.56%Tradable Shares19.02M
P/B--ROE--EPS0.00
52wk High--52wk Low--P/E--
Dividend--Div.Yield--ROA--

Loading ...

GeneDx Holdings Price Target Maintained with a $90.00/Share by BTIG
Dow Jones  ·  08-04 17:25
GeneDx Holdings Price Target Maintained with a $90.00/Share by BTIG
GeneDx Holdings Corp : Canaccord Genuity Raises Target Price to $90 from $75
THOMSON REUTERS  ·  08-04 16:36
GeneDx Holdings Corp : Canaccord Genuity Raises Target Price to $90 from $75
GeneDx Holdings Corp Reports Results for the Quarter Ended June 30 - Earnings Summary
Reuters  ·  08-04 05:55
GeneDx Holdings Corp Reports Results for the Quarter Ended June 30 - Earnings Summary
CORRECTION: GeneDx Hldgs Q2 Adj. EPS $0.01 Beats $(0.19) Estimate, Sales $114.440M Beat $111.011M Estimate
Benzinga Earnings  ·  08-04 05:31
CORRECTION: GeneDx Hldgs Q2 Adj. EPS $0.01 Beats $(0.19) Estimate, Sales $114.440M Beat $111.011M Estimate
GUIDANCE: (WGS) GeneDX Expects 2026 Revenue Range $475 Million - $490 Million, vs. FactSet Est of $478.4 Million
MT Newswires Live  ·  08-04 05:24
GUIDANCE: (WGS) GeneDX Expects 2026 Revenue Range $475 Million - $490 Million, vs. FactSet Est of $478.4 Million
GeneDx Q2 FY26 GAAP Net Loss Widens to $17.7 Million; Revenue Rises 11% Year over Year to $114.4 Million
Reuters  ·  08-04 04:13
GeneDx Q2 FY26 GAAP Net Loss Widens to $17.7 Million; Revenue Rises 11% Year over Year to $114.4 Million
GeneDx Q2 Revenue Beats Analyst Estimates
Reuters  ·  08-04 04:12
GeneDx Q2 Revenue Beats Analyst Estimates
GeneDx Hldgs Q2 Adj. EPS $(0.28) Misses $(0.19) Estimate, Sales $114.440M Beat $111.011M Estimate
Benzinga Earnings  ·  08-04 04:09
GeneDx Hldgs Q2 Adj. EPS $(0.28) Misses $(0.19) Estimate, Sales $114.440M Beat $111.011M Estimate
GeneDx Q2 Revenue USD 114.4 Million Vs. IBES Estimate USD 111 Million
Reuters  ·  08-04 04:06
GeneDx Q2 Revenue USD 114.4 Million Vs. IBES Estimate USD 111 Million
GeneDx: Q3 2026 Revenue Guidance $122 Mln-$124 Mln
THOMSON REUTERS  ·  08-04 04:05
GeneDx: Q3 2026 Revenue Guidance $122 Mln-$124 Mln
GeneDx Holdings: Reaffirmed Its Full Year 2026 Guidance
THOMSON REUTERS  ·  08-04 04:05
GeneDx Holdings: Reaffirmed Its Full Year 2026 Guidance
GeneDx Holdings Corp Q3 REV View $126.1 Mln
THOMSON REUTERS  ·  08-04 04:05
GeneDx Holdings Corp Q3 REV View $126.1 Mln
Press Release: GeneDx Reports Second Quarter 2026 Financial Results
Dow Jones  ·  08-04 04:05
Press Release: GeneDx Reports Second Quarter 2026 Financial Results
GeneDx Stock And 2 Testing Companies In Focus After Cyclospora Outbreak
Simply Wall St.  ·  07-28
GeneDx Stock And 2 Testing Companies In Focus After Cyclospora Outbreak
Earning Preview: GeneDx Holdings Q2 revenue is expected to increase by 29.92%, and institutional views are cautiously optimistic
Earnings Agent  ·  07-27
Earning Preview: GeneDx Holdings Q2 revenue is expected to increase by 29.92%, and institutional views are cautiously optimistic
How GeneDx’s Securities Lawsuit and Fabric Genomics Impairment Will Impact GeneDx Holdings (WGS) Investors
Simply Wall St.  ·  07-27
How GeneDx’s Securities Lawsuit and Fabric Genomics Impairment Will Impact GeneDx Holdings (WGS) Investors
Genedx to Report Q2 2026 Results After Market Close, Host Conference Call
Reuters  ·  07-17
Genedx to Report Q2 2026 Results After Market Close, Host Conference Call
How Investors Are Reacting To GeneDx Holdings (WGS) Class Actions Over Fabric Impairment And Guidance Cut
Simply Wall St.  ·  07-11
How Investors Are Reacting To GeneDx Holdings (WGS) Class Actions Over Fabric Impairment And Guidance Cut
Genedx Holdings is Maintained at Buy by Guggenheim
Dow Jones  ·  06-29
Genedx Holdings is Maintained at Buy by Guggenheim
Is GeneDx (WGS) Elevating Execution Risk or Opportunity With Its New Genomics-Focused President?
Simply Wall St.  ·  06-29
Is GeneDx (WGS) Elevating Execution Risk or Opportunity With Its New Genomics-Focused President?

Introduction

Company Name.
GeneDx Holdings
Affiliated Markets:
NASDAQ
Listing Date:
--
Main Business:
GeneDx Holdings Corp., through its subsidiaries, provides genomics-related diagnostic and information services. The company offers Centrellis, an AI-driven health intelligence platform that integrates digital tools and artificial intelligence allowing scientists to ingest and synthesize clinical and genomic data to deliver comprehensive health insights. It also provides genetic diagnostic tests, screening solutions, and information with a focus on pediatrics, rare diseases for children and adults, and hereditary cancer screening. GeneDx Holdings Corp. is headquartered in Stamford, Connecticut.
Issue price:
--